SynthesisBritish journal of clinical pharmacology2015
The blood pressure lowering potential of sulodexide--a systematic review and meta-analysis.
Synthesis in British journal of clinical pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Sulodexide for treating venous leg ulcers.The Cochrane database of systematic reviews · 2016Pooled it
- The blood pressure lowering potential of sulodexide--a systematic review and meta-analysis.British journal of clinical pharmacology · 2015Pooled it
- Distinct osmoregulatory responses to sodium loading in patients with altered glycosaminoglycan structure: a randomized cross-over trial.Journal of translational medicine · 2021Trial
- Blood pressure-lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies.British journal of clinical pharmacology · 2016Trial
- Salt and chronic kidney disease.Nature reviews. Nephrology · 2026Review
- Is It Time to Abandon the Kidney-Centered View on the Origin of Primary Hypertension?Hypertension (Dallas, Tex. : 1979) · 2025Review
- Glycocalyx disruption, endothelial dysfunction and vascular remodeling as underlying mechanisms and treatment targets of chronic venous disease.International angiology : a journal of the International Union of Angiology · 2024Review
- Sulodexide Inhibits Arterial Contraction via the Endothelium-Dependent Nitric Oxide Pathway.Journal of clinical medicine · 2024Article
- From salt to hypertension, what is missed?Journal of clinical hypertension (Greenwich, Conn.) · 2021Review
- Soluble syndecan-1 and glycosaminoglycans in preeclamptic and normotensive pregnancies.Scientific reports · 2021Article
- Mechanisms of Lower Extremity Vein Dysfunction in Chronic Venous Disease and Implications in Management of Varicose Veins.Vessel plus · 2021Article
- Clinical impact of tissue sodium storage.Pediatric nephrology (Berlin, Germany) · 2020Review
- Sodium-induced inflammation-an invisible player in resistant hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2020Review
- Body Fluid-Independent Effects of Dietary Salt Consumption in Chronic Kidney Disease.Nutrients · 2019Review
- Sulodexide promotes arterial relaxation via endothelium-dependent nitric oxide-mediated pathway.Biochemical pharmacology · 2019Article
- Abnormal sodium and water homeostasis in mice with defective heparan sulfate polymerization.PloS one · 2019Article
- The renoprotective effects of sulodexide.Drug design, development and therapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsSulodexide is a highly purified mixture of glycosaminoglycans that has been studied for its anti-albuminuric potential. Considering the effects of glycosaminoglycans on endothelial function and sodium homeostasis, we hypothesized that sulodexide may lower blood pressure (BP). In this meta-analysis, we therefore investigated the antihypertensive effects of sulodexide treatment.
methodsWe selected randomized controlled trials that investigated sulodexide treatment of at least 4 weeks and measured BP at baseline and after treatment. Two reviewers independently extracted data on study design, risk of bias, population characteristics and outcome measures. In addition, we contacted authors and pharmaceutical companies to provide missing data.
resultsEight studies, totalling 3019 subjects (mean follow-up 4.4 months) were included. Mean age was 61 years and mean baseline BP was 135/75 mmHg. Compared with control treatment, sulodexide resulted in a significant systolic (2.2 mmHg [95% CI 0.3, 4.1], P = 0.02) and diastolic BP reduction (1.7 mmHg [95% CI 0.6, 2.9], P = 0.004). Hypertensive patients displayed the largest systolic BP and diastolic BP reductions (10.2/5.4 mmHg, P < 0.001). Higher baseline systolic and diastolic BP were significantly associated with larger systolic (r(2)=0.83, P < 0.001) and diastolic BP (r(2)=0.41, P = 0.02) reductions after sulodexide treatment. In addition, systolic (r(2)=0.41, P = 0.03) and diastolic BP reductions (r(2)=0.60, P = 0.005) were significantly associated with albuminuria reduction.
conclusionOur data suggest that sulodexide treatment results in a significant BP reduction, especially in hypertensive subjects. This indicates that endothelial glycosaminoglycans might be an independent therapy target in cardiovascular disease. Future studies should further address the BP lowering potential of sulodexide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.